CEP 37440
Alternative Names: CEP-37440Latest Information Update: 04 Nov 2017
At a glance
- Originator Cephalon
- Developer Teva Pharmaceutical Industries
- Class Antineoplastics
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; PTK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO, Capsule)
- 01 Dec 2015 Teva Pharmaceutical Industries completes a phase I trial for Solid tumours (Late-stage disease) in USA (NCT01922752)
- 12 Aug 2013 Phase-I clinical trials in Solid tumours (late-stage disease) in USA (PO)